Talk:Ibrutinib

This is the talk page for discussing improvements to the Ibrutinib article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology High‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
High	This article has been rated as High-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Ibrutinib.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Can we reduce width on chembox on right

Currently (at least for me in Firefox) it looks about 40 chars wide and would be better at about half the current width. Can't see what sets the display width. - Rod57 (talk) 23:45, 9 April 2013 (UTC)[reply]

OK now. - Rod57 (talk) 14:15, 20 November 2016 (UTC)[reply]

Why no mention of atrial fibrillation as adverse effect

atrial fibrillation not mentioned in Adverse effects - despite efforts to treat IRAF eg [1], and that review saying different studies reported 5, 6 or 7% incidence of AF with ibrutinib use. - Rod57 (talk) 14:34, 20 November 2016 (UTC)[reply]

old refs. updated them, and content based on them. Jytdog (talk) 21:27, 20 November 2016 (UTC)[reply]

Bleeding

Is common doi:10.1111/jth.13651 JFW | T@lk 21:28, 2 May 2017 (UTC)[reply]

So common that this is the second review in a short period! doi:10.1182/bloodadvances.2016001883 JFW | T@lk 20:38, 9 May 2017 (UTC)[reply]

New text

"Ibrutinib is now the preferred first-line treatment for most patients with CLL"

One of the issue with this paper is that some of the authors are being paid by AbbVie.[2]

Add to that that the authors appear to be trying to add it themselves.

Table 2 lists a number of first line treatments. Doc James (talk · contribs · email) 18:27, 17 February 2019 (UTC)[reply]

Found a better ref, NCI. https://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq Doc James (talk · contribs · email) 00:38, 19 February 2019 (UTC)[reply]

US cost of Imbruvica -- reference, and add to Economic section

Treatment cost of Imbruvica $160,000 per year cited in Congressional hearing by Rep Ro Khanna of California on 10 Feb 2024. https://twitter.com/perry_ron/status/1756319357179953277 217.155.151.38 (talk) 12:40, 11 February 2024 (UTC)[reply]